Processing

Please wait...

Settings

Settings

Goto Application

1. WO2004106521 - CANINE CYP1A2 GENE POLYMORPHISM

Publication Number WO/2004/106521
Publication Date 09.12.2004
International Application No. PCT/JP2004/007356
International Filing Date 28.05.2004
Chapter 2 Demand Filed 28.07.2004
IPC
C12Q 1/68 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
CPC
C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
C12Q 2600/124
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
124Animal traits, i.e. production traits, including athletic performance or the like
C12Q 2600/136
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
136Screening for pharmacological compounds
C12Q 2600/142
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
142Toxicological screening, e.g. expression profiles which identify toxicity
C12Q 2600/156
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
156Polymorphic or mutational markers
Applicants
  • Astellas Pharma Inc. [JP]/[JP] (AllExceptUS)
  • 天水 大介 TENMIZU, Daisuke [JP]/[JP] (UsOnly)
  • 福永 泰久 FUKUNAGA, Yasuhisa [JP]/[JP] (UsOnly)
  • 野口 清 NOGUCHI, Kiyoshi [JP]/[JP] (UsOnly)
Inventors
  • 天水 大介 TENMIZU, Daisuke
  • 福永 泰久 FUKUNAGA, Yasuhisa
  • 野口 清 NOGUCHI, Kiyoshi
Agents
  • 森田 憲一 MORITA, Kenichi
Priority Data
2003-15291729.05.2003JP
2003-20658107.08.2003JP
Publication Language Japanese (ja)
Filing Language Japanese (JA)
Designated States
Title
(EN) CANINE CYP1A2 GENE POLYMORPHISM
(FR) POLYMORPHISME DU GENE CYP1A2 CANIN
(JA) イヌCYP1A2遺伝子多型
Abstract
(EN) It is intended to disclose a method of checking whether a dog is an extensive metabolizer or a poor metabolizer concerning drug metabolism speed which comprises obtaining a DNA sample from the dog and determining a base corresponding to the 1117-th base (namely, 87-th in the fourth exon) of its canine CYP1A2 gene. According to this method, CYP1A2 gene diagnosis of individual dogs (in particular, beagles) to be used in a pharmacological effect test or a toxicity test can be quickly carried out prior to the test. Thus, the subject dogs can be easily divided into a group having a normal metabolizing ability (an extensive metabolizer group) and a group having a low metabolizing ability (a poor metabolizer group).
(FR) L'invention concerne un procédé pour vérifier si un chien est un métabolisant faible ou extensif par rapport à la vitesse de métabolisme de médicaments, lequel procédé consiste à prélever un échantillon d'ADN sur le chien et à déterminer une base correspondant à la 1117e base (à savoir, 87e dans le quatrième exon) de son gène CYP1A2 canin. Selon ledit procédé, le diagnostic du gène CYP1A2 de chiens individuels (en particulier de beagles) destinés à être utilisés lors d'un test d'effet pharmacologique ou lors d'un test de toxicité peut être rapidement mis en oeuvre avant ce test. Ainsi, les sujets canins peuvent être facilement divisés en un groupe présentant une aptitude métabolisante normale (groupe métabolisant extensif) et un groupe présentant une faible aptitude métabolisante (groupe métabolisant faible).
(JA)  イヌからDNA試料を得、イヌCYP1A2遺伝子の1117番目(すなわち、第4エキソン87番目)の塩基に該当する塩基を決定することにより、薬物代謝速度がエクステンスィブ・メタボライザーであるか、又は、プアー・メタボライザーであるかを検出する方法を開示する。  前記方法によれば、イヌ(特にはビーグル犬)における薬理効果試験及び毒性試験の実施に先立ち、使用される個体のCYP1A2の遺伝子診断を迅速に実施し、正常な代謝能力を持つ群(エクステンスィブ・メタボライザー群)、又は、薬物代謝能力が低い群(プアー・メタボライザー群)に、簡便に群分けすることができる。
Latest bibliographic data on file with the International Bureau